BELLUS Health Inc. (BLU)
$14.745
+0.01 (+0.03%)
Rating:
Recommendation:
-
Symbol | BLU |
---|---|
Price | $14.745 |
Beta | -0.279 |
Volume Avg. | 5.38M |
Market Cap | 1.870B |
Shares () | - |
52 Week Range | 6.38-14.76 |
1y Target Est | - |
DCF Unlevered | BLU DCF -> | |
---|---|---|
DCF Levered | BLU LDCF -> | |
ROE | -24.27% | Sell |
ROA | -22.87% | Sell |
Operating Margin | - | |
Debt / Equity | 0.33% | Neutral |
P/E | -20.20 | Strong Sell |
P/B | 5.06 | Strong Buy |
Latest BLU news
About
Download (Excel)Mr. Roberto Francesco Bellini
Healthcare
Biotechnology
NASDAQ Global Select
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.